A Study of Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer | MicrobiomeTrials
A Study of Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2023-07-18Est. Completion: 2026-10-19
Enrollment target: 83 participants
Locations
Cancer Blood and Specialty Clinic, Los Alamitos, California, United States
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Novant Health Presbyterain Medical Center, Charlotte, North Carolina, United States
Avera Cancer Institute, Sioux Falls, South Dakota, United States
Centro de Investigaciones Médicas y Desarrollo LC S.R.L, Buenos Aires, Argentina
Sunshine Hospital, St Albans, Victoria, Australia
Hospital Araujo Jorge, Goiânia, Goiás, Brazil
Hospital do Cancer de Pernambuco - HCP, Recife, Pernambuco, Brazil
Hospital de Cancer de Barretos, Barretos, São Paulo, Brazil
Clinica de Pesquisa e Centro de Estudos em Oncologia Ginecologica e Mamaria Ltda, São Paulo, São Paulo, Brazil
Fakultni Thomayerova nemocnice, Praha 4 - Krc, Czechia